Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non...
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [ 18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
About this item
Full title
Author / Creator
Vera, Pierre, Prof , Thureau, Sébastien, Prof , Le Tinier, Florence, MD , Chaumet-Riffaud, Philippe, Prof , Hapdey, Sébastien, PhD , Kolesnikov-Gauthier, Hélène, MD , Martin, Etienne, MD , Berriolo-Riedinger, Alina, MD , Pourel, Nicolas, MD , Broglia, Jean Marc, MD , Boisselier, Pierre, MD , Guillemard, Sophie, MD , Salem, Naji, MD , Brenot-Rossi, Isabelle, MD , Le Péchoux, Cécile, MD , Berthold, Céline, MSc , Giroux-Leprieur, Etienne, Prof , Moreau, Damien, MSc , Guillerm, Sophie, MD , Benali, Khadija, MD , Tessonnier, Laurent, MD , Audigier-Valette, Clarisse, MD , Lerouge, Delphine, MD , Quak, Elske, MD , Massabeau, Carole, MD , Courbon, Frédéric, MD , Moisson, Patricia, MD , Larrouy, Anne, MD , Modzelewski, Romain, PhD , Gouel, Pierrick, PhD , Ghazzar, Nadia, MD , Langlais, Alexandra, MSc , Amour, Elodie, BEng , Zalcman, Gérard, Prof and Giraud, Philippe, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundThoracic radiation intensification is debated in patients with stage III non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of a boost radiotherapy dose up to 74 Gy in a functional sub-volume given according to on-treatment [ 18F]fluorodeoxyglucose ([ 18F]FDG)-PET results. MethodsIn this multicentre, ran...
Alternative Titles
Full title
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [ 18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Authors, Artists and Contributors
Author / Creator
Thureau, Sébastien, Prof
Le Tinier, Florence, MD
Chaumet-Riffaud, Philippe, Prof
Hapdey, Sébastien, PhD
Kolesnikov-Gauthier, Hélène, MD
Martin, Etienne, MD
Berriolo-Riedinger, Alina, MD
Pourel, Nicolas, MD
Broglia, Jean Marc, MD
Boisselier, Pierre, MD
Guillemard, Sophie, MD
Salem, Naji, MD
Brenot-Rossi, Isabelle, MD
Le Péchoux, Cécile, MD
Berthold, Céline, MSc
Giroux-Leprieur, Etienne, Prof
Moreau, Damien, MSc
Guillerm, Sophie, MD
Benali, Khadija, MD
Tessonnier, Laurent, MD
Audigier-Valette, Clarisse, MD
Lerouge, Delphine, MD
Quak, Elske, MD
Massabeau, Carole, MD
Courbon, Frédéric, MD
Moisson, Patricia, MD
Larrouy, Anne, MD
Modzelewski, Romain, PhD
Gouel, Pierrick, PhD
Ghazzar, Nadia, MD
Langlais, Alexandra, MSc
Amour, Elodie, BEng
Zalcman, Gérard, Prof
Giraud, Philippe, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_04783212v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04783212v1
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(24)00320-6
